US Congress confirms new drug patent listing law

A $2.3 trillion spending bill passed by the US Congress yesterday, December 21 includes a proposed change to the laws concerning biologic drugs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Diabetics to benefit under latest FDA biosimilar guidance

13 May 2019 The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.

Americas

AstraZeneca asks FDA to delay ANDAs for Crestor generics

14 June 2016 AstraZeneca has filed a citizen petition to the US Food and Drug Administration requesting it to wait until 2023 before approving generic versions of Crestor, a cholesterol treatment.

More on this story

Americas

Diabetics to benefit under latest FDA biosimilar guidance

13 May 2019 The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.

Americas

AstraZeneca asks FDA to delay ANDAs for Crestor generics

14 June 2016 AstraZeneca has filed a citizen petition to the US Food and Drug Administration requesting it to wait until 2023 before approving generic versions of Crestor, a cholesterol treatment.

More on this story

Americas

Diabetics to benefit under latest FDA biosimilar guidance

13 May 2019 The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.

Americas

AstraZeneca asks FDA to delay ANDAs for Crestor generics

14 June 2016 AstraZeneca has filed a citizen petition to the US Food and Drug Administration requesting it to wait until 2023 before approving generic versions of Crestor, a cholesterol treatment.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB

US Congress confirms new drug patent listing law

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features